Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 20
2003 37
2004 22
2005 23
2006 26
2007 26
2008 32
2009 34
2010 45
2011 45
2012 43
2013 48
2014 50
2015 59
2016 55
2017 65
2018 70
2019 51
2020 69
2021 81
2022 73
2023 60
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

901 results

Results by year

Filters applied: . Clear all
Page 1
Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
DiNardo CD, Roboz GJ, Watts JM, Madanat YF, Prince GT, Baratam P, de Botton S, Stein AS, Foran JM, Arellano ML, Sallman DA, Hossain M, Marchione DM, Bai X, Patel PA, Kapsalis SM, Garcia-Manero G, Fathi AT. DiNardo CD, et al. Among authors: garcia manero g. Blood Adv. 2024 Apr 19:bloodadvances.2023012302. doi: 10.1182/bloodadvances.2023012302. Online ahead of print. Blood Adv. 2024. PMID: 38640348
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
Abuasab T, Borthakur G, Kanagal-Shamanna R, Masarova L, Patel K, Takahashi K, Bose P, Villarreal J, Pierce S, Kadia T, Garcia-Manero G, Short NJ, DiNardo C, Daver N, Ravandi F, Kantarjian H, Verstovsek S, Yilmaz M. Abuasab T, et al. Among authors: garcia manero g. Am J Hematol. 2024 Apr 13. doi: 10.1002/ajh.27333. Online ahead of print. Am J Hematol. 2024. PMID: 38613831 No abstract available.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Jabbour E, et al. Among authors: garcia manero g. Cancer. 2024 Apr 9. doi: 10.1002/cncr.35317. Online ahead of print. Cancer. 2024. PMID: 38591430
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Bose P, et al. Among authors: garcia manero g. Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2023.284078. Online ahead of print. Haematologica. 2024. PMID: 38572554 Free article. No abstract available.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS PhD, Qu C, Macaron W, Jain N, Thakral B, Phillips A, Khoury JD, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris R, Nasr LF, Kriwacki R, Roberts KG, Konopleva MY, Jabbour EJ, Mullighan CG. Zhao Y, et al. Among authors: garcia manero g. Blood. 2024 Mar 29:blood.2024023930. doi: 10.1182/blood.2024023930. Online ahead of print. Blood. 2024. PMID: 38551807
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Bazinet A, et al. Among authors: garcia manero g. Lancet Haematol. 2024 Apr;11(4):e287-e298. doi: 10.1016/S2352-3026(24)00034-6. Lancet Haematol. 2024. PMID: 38548404 Clinical Trial.
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
Bataller A, Gener-Ricos G, Almanza E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Bataller A, et al. Among authors: garcia manero g. Blood Adv. 2024 Mar 21:bloodadvances.2024012565. doi: 10.1182/bloodadvances.2024012565. Online ahead of print. Blood Adv. 2024. PMID: 38513082
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes.
Rodriguez-Sevilla JJ, Ganan-Gomez I, Ma F, Chien K, Del Rey M, Loghavi S, Montalban-Bravo G, Adema V, Wildeman B, Kanagal-Shamanna R, Bazinet A, Chifotides HT, Thongon N, Calvo X, Hernández-Rivas JM, Díez-Campelo M, Garcia-Manero G, Colla S. Rodriguez-Sevilla JJ, et al. Among authors: garcia manero g. Nat Commun. 2024 Mar 18;15(1):2428. doi: 10.1038/s41467-024-46424-3. Nat Commun. 2024. PMID: 38499526 Free PMC article.
901 results